Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?

Detalles Bibliográficos
Autor principal: Riva, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa UK, Ltd. 2013
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833714/
https://www.ncbi.nlm.nih.gov/pubmed/23931143
http://dx.doi.org/10.1517/14740338.2013.829452
_version_ 1782291883798560768
author Riva, Alessandro
author_facet Riva, Alessandro
author_sort Riva, Alessandro
collection PubMed
description
format Online
Article
Text
id pubmed-3833714
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Informa UK, Ltd.
record_format MEDLINE/PubMed
spelling pubmed-38337142013-12-03 Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Riva, Alessandro Expert Opin Drug Saf Letter to the Editor Informa UK, Ltd. 2013-09 2013-08-12 /pmc/articles/PMC3833714/ /pubmed/23931143 http://dx.doi.org/10.1517/14740338.2013.829452 Text en © Informa UK, Ltd.
spellingShingle Letter to the Editor
Riva, Alessandro
Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
title Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
title_full Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
title_fullStr Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
title_full_unstemmed Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
title_short Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
title_sort comment on: a record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833714/
https://www.ncbi.nlm.nih.gov/pubmed/23931143
http://dx.doi.org/10.1517/14740338.2013.829452
work_keys_str_mv AT rivaalessandro commentonarecordnumberoffatalitiesinmanycategoriesofpatientstreatedwithdeferasiroxloopholesinregulatoryandmarketingproceduresunderminepatientsafetyandmisguidepublicfunds

Ejemplares similares